ORAGENICS, INC. Interest Expense Nonoperating
ORAGENICS, INC. (OGEN) reported Interest Expense Nonoperating of $414 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- ORAGENICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $414.00, a 99.93% decline year-over-year.
- ORAGENICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $3.73K, a 98.13% decline year-over-year.
- ORAGENICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $7.45K, a 32.04% decline year-over-year.
- ORAGENICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $7.04K, a 29.41% decline year-over-year.
- ORAGENICS, INC. interest expense nonoperating for fiscal 2025 was $785.93K, a 2534.87% increase from fiscal 2024.
- ORAGENICS, INC. interest expense nonoperating for fiscal 2024 was $29.83K, a 2.49% decline from fiscal 2023.
- ORAGENICS, INC. interest expense nonoperating for fiscal 2023 was $30.59K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $414.00 10-Q · filed 2026-08-13 | $4.14K 10-Q · filed 2026-08-13 | $11.60K derived: sum of 3 quarters · filed 2026-08-13 | $18.63K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.73K 10-Q · filed 2026-05-08 | $11.18K derived: sum of 2 quarters · filed 2026-05-08 | $18.22K derived: sum of 3 quarters · filed 2026-05-08 | $590.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $7.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $14.49K derived: sum of 2 quarters · filed 2026-03-16 | $586.80K derived: sum of 3 quarters · filed 2026-08-13 | $785.93K 10-K · filed 2026-03-16 |
| 2025-09-30 | $7.04K 10-Q · filed 2025-11-07 | $579.35K derived: sum of 2 quarters · filed 2026-08-13 | $778.48K 10-Q · filed 2025-11-07 | $789.45K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $572.31K 10-Q · filed 2026-08-13 | $771.44K 10-Q · filed 2026-08-13 | $782.41K derived: sum of 3 quarters · filed 2026-08-13 | $792.38K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $199.13K 10-Q · filed 2026-05-08 | $210.10K derived: sum of 2 quarters · filed 2026-05-08 | $220.07K derived: sum of 3 quarters · filed 2026-05-08 | $221.87K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $10.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $20.94K derived: sum of 2 quarters · filed 2026-03-16 | $22.74K derived: sum of 3 quarters · filed 2026-03-16 | $29.83K 10-K · filed 2026-03-16 |
| 2024-09-30 | $9.97K 10-Q · filed 2025-11-07 | $11.77K derived: sum of 2 quarters · filed 2025-11-07 | $18.86K 10-Q · filed 2025-11-07 | $31.09K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.80K 10-Q · filed 2025-08-08 | $8.89K 10-Q · filed 2025-08-08 | $21.12K derived: sum of 3 quarters · filed 2025-08-08 | $35.29K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $7.08K 10-Q · filed 2025-05-09 | $19.32K derived: sum of 2 quarters · filed 2025-05-09 | $33.49K derived: sum of 3 quarters · filed 2025-05-09 | $34.33K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $12.23K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $26.40K derived: sum of 2 quarters · filed 2025-03-14 | $27.24K derived: sum of 3 quarters · filed 2025-03-14 | $30.59K 10-K · filed 2025-03-14 |
| 2023-09-30 | $14.17K 10-Q · filed 2024-11-13 | $15.01K derived: sum of 2 quarters · filed 2024-11-13 | $18.36K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $843.00 10-Q · filed 2024-08-09 | $4.19K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |